Resmetirom is an oral, first, liver-directed, selective thyroid hormone receptor - beta (THR-β) agonist approved by US FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Copyright © All Rights Reserved by Azista Bhutan Healthcare Limited.
